Clinical and immunologic impact of short-course enzalutamide alone and with immunotherapy in non-metastatic castration sensitive prostate cancer

Clinical and immunologic impact of short-course enzalutamide alone and with immunotherapy in non-metastatic castration sensitive prostate cancer

Background The standard treatment for non-metastatic castration sensitive prostate cancer (nmCSPC) is androgen deprivation therapy (ADT) or surveillance. This study evaluated the potential synergy of immunotherapy and enzalutamide (without ADT) in nmCSPC. In addition, the immunologic impact of enzal...

Full description

Bibliographic Details
Main Authors: Harpreet Singh, Seth Steinberg, Lisa Cordes, Helen Owens, Amy Hankin, Anna Couvillon, Marc R Theoret, Munjid Al-Harthy, Inger I Rosner, Philip M Arlen, Moniquea Williams, Sarah E Lochrin, Cindy H Chau, William Douglas Figg, William Dahut
Format: Article
Language:English
Published: BMJ Publishing Group 2021-03-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/9/3/e001556.full

Internet

https://jitc.bmj.com/content/9/3/e001556.full

Similar Items